Announcements Trials
Browse Landscape

Phase

Phase NA 2

Status

Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1Gastrointestinal 1Breast 1

Conditions

Lymphoma 4Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Breast Neoplasms 2Recurrence 1Prostatic Neoplasms 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Hodgkin Disease 1Colonic Neoplasms 1Caregiver Burden 1

Interventions

pembrolizumab 180Gemcitabine 168Paclitaxel 150Carboplatin 134Bevacizumab 126Cisplatin 113Docetaxel 112Cyclophosphamide 109Exercise 97Nivolumab 93Fluorouracil 88Capecitabine 85Dexamethasone 81Irinotecan 74Radiotherapy 68Oxaliplatin 68Pemetrexed 66Standard of Care 64Leucovorin 63Cetuximab 59Sorafenib 53Erlotinib Hydrochloride 53Drug Therapy 53Blood Specimen Collection 51Doxorubicin 50atezolizumab 48trametinib 47Ipilimumab 47Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Neoplasms × Health Resources × Clear all
NCT06605196 2026-02-04

AHD

Washington University School of Medicine

Phase NA Not yet recruiting
364 enrolled
Tumor-Agnostic

Neoplasms

NCT04685551 2022-07-26

Improving Survivorship Among Minority Cancer Dyads

Charles Drew University of Medicine and Science

Phase NA Withdrawn
BreastGastrointestinalThoracic

Caregiver Burden, Breast Neoplasms, Colonic Neoplasms, Lung Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡